| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004421 | American Journal of Ophthalmology | 2009 | 5 Pages |
Abstract
The current study appears to show that the glitazone class of drug is associated with DME. After adjusting for confounding factors of age, glycemic control, and insulin use, glitazones are still modestly associated with DME. A more in-depth study will need to be done to evaluate the role of other confounding factors. When treating patients with DME, ophthalmologists should consider the role of the glitazones.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Donald S. Fong, Richard Contreras,